Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, ...

Core Insights - Biogen's 4Q25 earnings reflect a transition rather than pure growth, indicating a strategic shift as the company moves away from a declining multiple sclerosis (MS) market [1] Company Overview - Biogen is successfully transitioning from a shrinking MS market, suggesting a focus on new growth opportunities [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The analyst has been active in the investing space for five years, with a focus on identifying promising biotechnology companies and evaluating their scientific and financial fundamentals [1] Investment Focus - The analysis emphasizes the importance of evaluating the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals [1]

医药生物 2026年02月09日 《本周申万医药生物指数下跌 0.4%，关注 AI 制药板块 -- 医药行业周报 (2026/01/19-2026/01/23) 》 2026/01/25 《本周申万医药生物指数下跌 0.7%，关注 CXO 板块投资机会――医药行业周报 (2026/01/12-2026/01/16) 》 2026/01/18 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 陈田甜 A0230524080013 chentt@swsresearch.com 联系人 陈田甜 A0230524080013 chentt@swsresearch.com 申万宏源研究微信服务号 本 周 申 万 医 药 生 物 指 数 上 涨 0.14%, 关注中药高质量发展方案 —— 医药行业周报（2026/02/02-2026/02/06 \ 本期投资后了 请务必仔细阅读正文之后的各项信息披露与声明 手机 相关研究 市场表现：本周申万医药生物指数上涨 0.1%，同期上证指数下跌 1.27%，万得全 A (除金融石油石化）下跌 1.8%。本周医药生物指数在 31 个申万 ...

相关研究 《本周申万医药生物指数下跌 0.4%，关注 AI 制药板块 ——医药行业周报 （2026/01/19-2026/01/23）》 2026/01/25 《本周申万医药生物指数下跌 0.7%，关注 CXO 板块投资机会——医药行业周报 （2026/01/12-2026/01/16）》 2026/01/18 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 陈田甜 A0230524080013 chentt@swsresearch.com 联系人 行 业 及 产 业 医药生物 行 业 研 究 / 行 业 点 评 证 券 研 究 报 告 行业点评 陈田甜 A0230524080013 chentt@swsresearch.com 2026 年 02 月 09 日 本 周 申 万 医 药 生 物 指 数 上 涨 0.14%，关注中药高质量发展方案 看好 —— 医药行业周报（2026/02/02-2026/02/06） 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 博时基金 博时基金管理有限公司(researchrepor ...

Core Viewpoint - Eisai Co., Ltd. and Biogen Inc. announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI has been designated for Priority Review by the National Medical Products Administration of China, which could significantly enhance patient access to treatment [1][2]. Group 1: Product Development and Approval - The subcutaneous formulation (SC-AI) of LEQEMBI allows for a once-weekly home administration, contrasting with the current intravenous method that requires hospital visits every two weeks [3]. - The injection time for each autoinjector is approximately 15 seconds, which could streamline the treatment process and reduce healthcare resource utilization [3]. - Eisai estimates that there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China in 2024, a number expected to rise with the aging population [4]. Group 2: Market Access and Insurance - LEQEMBI was launched in China in June 2024 and has been included in the "Commercial Insurance Innovative Drug List," effective January 2026, which supports access to innovative medicines [5]. - Commercial insurance companies are expected to develop insurance products covering LEQEMBI based on this new list [5]. Group 3: Collaboration and Regulatory Strategy - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [6][11]. - The U.S. FDA approved the Biologics License Application for subcutaneous maintenance dosing of LEQEMBI in August 2025, with a supplemental application for initiation treatment accepted in January 2026 [8]. Group 4: Scientific Background - Lecanemab is a humanized monoclonal antibody targeting aggregated forms of amyloid-beta, which is believed to play a significant role in cognitive decline associated with Alzheimer's disease [8][10]. - The reduction of protofibrils may prevent the progression of Alzheimer's disease by mitigating neuronal damage and cognitive dysfunction [10]. Group 5: Company Overview - Eisai's corporate concept focuses on patient-centric healthcare, aiming to address unmet medical needs, particularly in neurology and oncology [13]. - Biogen, founded in 1978, is a leading biotechnology company that emphasizes innovative science to transform patient lives and create shareholder value [16].

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus estimate of $1.59 [1] - The company generated revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although this represents a 7% decline on both a reported and constant currency basis [1] Drug Performance - Fiscal 2025 revenue from growth products increased by 19% year-over-year, which helped offset the decline in revenue from multiple sclerosis products, excluding Vumerity [2] - Leqembi, an Alzheimer's drug, generated collaboration revenue of $47 million, with in-market sales reaching approximately $134 million, reflecting a 54% increase [3] - Multiple sclerosis revenue totaled $917 million, down 14% year-over-year (15% decline on a constant currency basis), with Tysabri sales decreasing from $415.4 million to $397.5 million [3] Rare Disease Revenue - Revenue from rare diseases decreased by 4% year-over-year to $514.6 million, with Spinraza's revenue declining from $421.4 million to $356.2 million [4] - Spinraza's fourth-quarter revenue fell by 15% year-over-year, influenced by shipment timing outside the U.S., while full-year revenue was down 2% [4] New Product Contributions - Skyclarys, a drug for Friedreich's ataxia, reported revenues of $133.4 million during the quarter, up from $102.2 million a year ago [5] - Skyclarys saw a 30% increase in global patients on therapy in 2025, with U.S. revenue of approximately $89 million driven by demand growth [6] - Zurzuvae, a postpartum depression drug, achieved fourth-quarter revenue of approximately $66 million, indicating strong demand growth [6] - Vumerity's revenue grew by 3% year-over-year in the fourth quarter to $181.1 million [6] Management Commentary - The President and CEO of Biogen highlighted that the 2025 performance was driven by nearly $1 billion in revenue from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, along with pipeline progression and the resilience of the MS franchise [7]

Evan Seigerman from BMO Capital has set a new price target of $196 for Biogen Inc. (NASDAQ:BIIB), indicating a positive outlook on the company's performance.The stock's current price of $201.18 is approximately 2.57% above the new target, showcasing investor confidence and an 8.53% increase in market activity.Biogen's recent Q4 2025 earnings call provided insights into the company's financial health, with a focus on revenue, profit margins, and strategic initiatives.Biogen Inc. (NASDAQ:BIIB) is a leading bi ...

Biogen's EPS of $1.99 in Q4 2025 surpassed Zacks Consensus Estimate, despite a 42% decline from the previous year.The company's total revenue of $2.28 billion for Q4 2025 exceeded expectations, with newer drugs partially offsetting declines in key MS and SMA drug sales.Following optimistic 2026 EPS guidance, Biogen's stock price increased to $201.18, marking an 8.53% rise.Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company focused on discovering, developing, and delivering therapies for neurologica ...

It's obvious that the company has a good shot at returning to growth.One of the healthier stocks on the market Friday was veteran biotech Biogen (BIIB +8.82%). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both trailing and forward profitability. It was little wonder that impressed market players piled into the stock, leaving it with a nearly 9% gain on the day.Fine despite the declinesBiogen's fourth quarter saw the company book total revenue of almost $2 ...